Non-Injectable Insulin Companies | Forecast by 2033

09 Aug 2024

Share :

Table of Content

1. Non-Injectable Insulin Market Growth and Trends 2. Market Overview 3. Non-Injectable Insulin Market Emerging Trends 4. Top Companies in the Non-Injectable Insulin Market 5. Regional Insights 6. Market Potential and Growth Opportunity 7. Non-Injectable Insulin Market Highlights 8. Non-Injectable Insulin Market News

Non-Injectable Insulin Market Growth and Trends

The global non-injectable insulin market was evaluated at USD 1.47 billion in 2023 and is anticipated to be attain around USD 5.08 billion by 2033, expanding at a CAGR of 12.99% during the forecast period. The market includes options such as oral medication, patches, inhalable forms, and various other forms of insulin intake. Due to poor lifestyle, food habits, and many other factors, diabetes cases are growing rapidly, hence the market.

The Full Study is Readily Available | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/3412

Market Overview

This non-injectable insulin market consists of various forms of insulin formulation customized for administration apart from injections, providing several alternatives to people suffering from diabetes. There are many oral options available in today’s market to treat diabetes, such as metformin, sulphonylureas, meglitinides, and several others. For instance, according to the National Institute of Health (NIH), more than 180 million people are suffering from diabetes mellitus, and nearly around 2.9 million deaths are occurring due to this. Diabetes is a disease that occurs due to increased blood glucose or blood sugar levels in the body. There are various types of diabetes. The most common are type 2 diabetes, type 1 diabetes, prediabetes, gestational diabetes, and many others.

Non-Injectable Insulin Market Emerging Trends

Revolutionization in diabetes management: Continuous research is being conducted to comfort people suffering from diabetes, which ultimately boosts the non-injectable insulin market. This innovation in diabetes management provides alternatives to needles, and many orally consuming options are introduced.

Strict evaluation: Regulatory bodies such as the FDA have introduced strict guidelines for approving insulin medicines to ensure the quality of the medicines available in the market. Such strict evaluation of medicines supports the development of the best products and improves people's preferences for them.

Collaboration among companies: To provide better non-injectable insulin medications, many pharmaceutical companies collaborate with IT companies for various purposes, such as delivering products, tracking public demands, and more. Pharmaceutical companies are also collaborating with healthcare experts, which helps to boost the market.

Continuous research towards painless options for diabetes patients driving the non-injectable insulin market

The non-injectable insulin market is growing significantly as there are several options available currently in this field. Several medicines serving quality treatment include SGLT2 inhibitors, Alpha-glucosidase inhibitors, Pramlintide, Biguanide, Bile acid sequestrant, Canagliflozin, and many more. The inhibitors available in the market work by inhibiting sodium-glucose transport proteins in the nephron. Diabetes is considered a chronic disease that occurs for two reasons: the pancreas reduces the production of insulin, or the body is unable to use the insulin it produces. Many government and non-governmental organizations work together to achieve this.

• For instance, the WHO aimed to assist and stimulate the acceptance of effective procedures for diagnosing, controlling, and preventing diabetes. The measures taken by the WHO include providing scientific guidelines for the prevention of diabetes, developing norms for diabetes diagnosis, spreading awareness related to the worldwide epidemic of diabetes, and conducting surveillance of diabetes and the risks associated with it.  The government conducts several awareness programs to inform people about diabetes. Companies also develop various insulin pumps as a non-injectable diabetes treatment.
• For instance, in May 2022, the World Health Assembly recommended five worldwide diabetes reporting and treatment targets to be attained by the end of 2030.
• For instance, the U.S. Food and Drugs Administration has approved Lyumjev®, developed by a company named Eli Lilly and Company, which is a rapid-acting insulin to improve glycemic control in adults suffering from type 1 and 2 diabetes.

However, non-injectable insulin is costly, and not everyone can afford it. People who belong to the lower and middle classes cannot afford such devices; apart from this, people from rural areas are not aware of such gadgets, which restrain the market growth. It is highly important to come up with solutions that will reduce the cost of the devices, and people will become more aware of such things.

Top Companies in the Non-Injectable Insulin Market

• Eli Lily
• Novo Nordisk
• Biocon
• Mankind Corporation
• Sanofi
• Adocia
• Medtronics
• Senseonics
• Dance Biopharm
• Jannsen Pharmaceuticals
• Oramed Pharmaceuticals
• Zafgen
• Bigfoot Biomedical
• Verily Life Sciences

Recent Development by Sanofi

• In March 2023, Sanofi, which is a global pharmaceutical company that is dedicated to improving various lives through discovering and developing effective medications and vaccines, announced the launch of Soliqua, which is a diabetes drug authorized by the Central Drugs Standard Control Organization (CDSCO).

Recent Development by Medtronic

• In May 2023, Medtronic, which is a medical technology company that designs, develops, and manufactures medical devices and solutions, announced its collaboration with EOFlow Co. Ltd. and launched the EOPatch® device, which is a tubeless, wearable, and disposable insulin delivery device.

Regional Insights

Asia-Pacific is estimated to grow at the fastest rate during the forecast period due to developing countries like China, India, Japan, and many others. Many companies collaborate with government plans to spread awareness and develop painless methods of insulin administration. Diabetes become a major reason for concern for all due to its continuously rising cases.

• For instance, according to the International Diabetes Federation, 11.8% of Japanese people are suffering from diabetes, and the percentage is growing rapidly.

To resolve these issues, companies are launching products that are painless as well.

• For instance, in December 2022, Terumo Corporation announced that medical insurance would be covered for all Dexcom G6 CGM system users for Insulin Therapy in Japan.

North America dominated the non-injectable market in 2023 due to several factors, such as awareness among people and demand for painless insulin administration. Rising cases of diabetes and its consequences are also compelling the market players to introduce improved quality medicines. The continuous efforts with the introduction of medicines drive the non-injectable insulin market to grow rapidly. By cutting down the price of such medicines, the dominating market players are making them affordable for people belonging to all categories.

• For instance, according to the Centers for Disease Control and Prevention (CDC), in the U.S., approximately 38.4 million people are suffering from diabetes. Also, in Canada, it is estimated that nearly 3.7 million people living who are diagnosed with diabetes.
• For instance, Eli Lily and the company announced a price reduction of up to 70% of its insulin drugs, which are the most prescribed.

Market Potential and Growth Opportunity

The rising number of patients boosting the non-injectable insulin market to expand

The growing cases of diabetes across the globe in all age groups are boosting the market players to expand the innovation of non-injectable insulin. Medicines such as Dopamine-2 agonists help to reset the hypothalamic circadian rhythm, resulting in reverse insulin resistance and causing a drop in glucose production in the liver. DDP-4 inhibitors (gliptins) help to improve blood sugar levels by preventing the breakdown of GLP-1.  Six alternatives are available for insulin injections: nasal insulin, insulin pumps, exubera, afrezza, artificial pancreas, and bionic pancreas.

Insulin helps move glucose from the bloodstream to the body's cells to produce energy. It is made by beta cells in the pancreas. This non-injectable market is introduced to add convenience to diabetes people's continuous practice, which is going on to provide better quality medicines in place of injections.

The market players dominating this field are Novo Nordisk, Medtronic, Zafgen, Adocia, Biocon, and many other options are available. The unawareness regarding non-injectable insulin administration among people causes unacceptance of such medications, which ultimately hinders the growth of the non-injectable insulin market. The psychological belief associated with insulin injections led to the decline of the non-injectable market. Healthcare experts need to support these medications in promoting the market to avoid such circumstances.

Non-Injectable Insulin Market Highlights

Non-Injectable Insulin Market News

• In November 2023, NiedlFree Technologies, a transgene biotech company, announced the launch of an oral insulin spray, Ozulin. This spray is a needle-free insulin administration alternative beneficial for both humans and animals.
• In October 2022, Glenmark Pharmaceuticals launched the Thiazolidinedione Lobeglitazone drug. This drug works as an insulin sensitizer, improving glycemic levels for people suffering from diabetes.

Market Segmentation

By Product

• Pills
• Sprays
• Others

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Drug Stores

Buy this Research Report@ https://www.precedenceresearch.com/checkout/3412

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308